EU First To Approve Novartis’s Cholesterol Drug Leqvio
Twice Yearly Dosing Is Key Selling Point
Novartis hopes its new RNAi-based therapy will be a blockbuster – but must eventually show it can cut heart attacks and cardiovascular deaths.
You may also be interested in...
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Partnership includes provision for fast-tracked uptake of inclisiran in England, if NICE finds it cost effective.